Clavis reports 50% remission in Phase II for acute myeloid lymphoma combo
This article was originally published in Scrip
Executive Summary
Norway’s Clavis Pharma has reported 'encouraging' interim results from a Phase II trial investigating its lead product, elacytarabine, in combination with idarubicin in patients with early stage acute myeloid lymphoma (AML) who have failed cytarabine-containing first-course chemotherapy.